AstraZeneca PLC (BCBA:AZN)

Market Cap	367.58T
Revenue (ttm)	67.33T
Net Income (ttm)	9.89T
Shares Out	n/a
EPS (ttm)	6,326.07
PE Ratio	37.19
Forward PE	16.77
Dividend	795.69 (1.30%)
Ex-Dividend Date	Aug 8, 2025

Volume	229
Average Volume	862
Open	61,275
Previous Close	61,250
Day's Range	60,975 - 62,100
52-Week Range	34,800 - 67,775
Beta	n/a
RSI	50.46
Earnings Date	Nov 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 94,300
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: AZN

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD